MRM-HEALTH
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced it will present positive data for its lead asset, MH002, a live microbial consortium therapy for Inflammatory Bowel Diseases, in two oral presentations during the 2024 Digestive Disease Week® (DDW) meeting, being held May 18-21, 2024 in Washington, D.C. at the Walter E. Washington Convention Center.
Late Breaker Presentation Details
Session Title: IMIBD Late Breakers and Innovations in IBD
Presentation Title: Safety and Efficacy of MH002, an Optimized Live Biotherapeutic Product, for the Treatment of Mild to Moderate Ulcerative Colitis: A First-in-Disease, Double-Blind, Randomized Clinical Trial
Presenter: Séverine Vermeire, Ph.D., Principal Investigator and Scientific Advisor of MRM Health
Date and Time: Sunday, May 19, 2024, 3:15 PM – 3:30 PM EDT
Location: Ballroom B
Poster of Distinction Presentation Details
Session Title: Microbial Therapies for GI Disease
Session Sponsor: AGA
Presentation Title: MH002, an Optimized Live Biotherapeutic Product for the Treatment of Inflammatory Bowel Diseases, Has Mode-of-Actions Linked to Restoration of Intestinal Dysbiosis, Mucosal Integrity, and Immune Homeostasis
Poster Number: Mo1919
Presenter: Sam Possemiers, Ph.D., Chief Executive Officer of MRM Health
Date and Time: Monday, May 20, 2024, 12:30 PM – 1:30 PM EDT
This poster has been selected by DDW as a “Poster of Distinction,” recognizing the top 10% of all AGA abstracts selected for poster presentation.
Key findings that will be presented include:
- The primary endpoint from a placebo-controlled Phase 2a trial in mild-to-moderate Ulcerative Colitis patients was met, with an excellent safety profile and tolerance at a fixed dose of 400mg per day over 16 weeks administration.
- Initial efficacy on disease activity was evidenced in clinically relevant parameters, including a 12% improvement in Mayo Endoscopic Severity (MES) score (p=0.05, 1-sided Wilcoxon rank sum test), while placebo worsened by 5%. Stool consistency significantly improved in the MH002 treatment group as from week 2 (p=0.006; 1-sided Student t-test). At the end of the eight-week period, 18% of subjects achieved clinical remission compared to 0% of the placebo group (Per-protocol analysis). In contrast to previous trials with other live biotherapeutics in UC, this study was performed successfully without vancomycin preconditioning.
- At a mechanistic level, anti-inflammatory effect was demonstrated with a 42% decrease in median fecal calprotectin (a clinically relevant bowel inflammation marker) compared to 18% in placebo at week 8. Furthermore, microbiome restoration occurred in parallel with clinical effects, and differential gene expression analysis showed downregulation of genes involved in inflammation. These findings were in line with the mode-of-action of MH002 and linked to restoration of intestinal dysbiosis, mucosal integrity, and immune homeostasis.
-Ends-
About MH002
MH002 is currently the most advanced rationally designed live microbial consortium therapy in Inflammatory Bowel Diseases, having demonstrated safety and efficacy in phase 2a trials in both Ulcerative Colitis and Pouchitis. It was developed through MRM Health’s proprietary CORAL® Technology and comprises six well-characterized and safe commensal strains, selected and optimized to tackle key disease-driving mechanisms with enhanced potency, resiliency, and engraftment. MRM Health’s breakthrough scalable and standardized cGMP manufacturing platform allows for the manufacturing of complete consortia as a single drug substance. This ability of CORAL® to enable scalable, cost-effective manufacturing of complete optimized consortia in a single process is expected to provide both key regulatory and patient compliance advantages.
About MRM Health
MRM Health is a clinical-stage biotech developing innovative therapeutics for inflammatory, CNS and metabolic diseases. The Company’s most advanced program MH002 is in preparation for pivotal clinical development in Ulcerative Colitis and/or in the orphan disease indication Pouchitis. MRM Health leverages its proprietary disruptive CORAL® technology platform to design microbiome-based biotherapeutics, based on disease-focused specific combinations of 5 to 10 live gut bacteria, and to optimize them for faster onset-of-action and increased potency and robustness. A significant differentiator is the ability to manufacture these consortia as single drug substance in a single standardized, scalable and highly cost-effective process. In addition to the program in Inflammatory Bowel Diseases, MRM Health has ongoing preclinical programs in Parkinson’s Disease and Spondyloarthritis, and partnered programs with IFF in Type 2 Diabetes and NAFLD.
For more information, please visit the website at www.mrmhealth.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515115683/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AB InBev Reports Third Quarter 2025 Results30.10.2025 07:05:00 CET | Press release
Consistent execution of our strategy delivered an EBITDA increase of 3.3% with margin expansion and low-single digit Underlying EPS growth Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029571716/en/ Regulated and inside information1 “Driven by the momentum of our megabrands and our innovation in balanced choices and Beyond Beer, our business delivered continued top- and bottom-line growth, even as we navigated a dynamic consumer environment. Given the progress we have made on our deleveraging and solid year-to-date financial results we have announced a new 6 billion USD share buyback program and an interim dividend.” – Michel Doukeris, CEO, AB InBev Revenue +0.9% Revenue increased by 0.9% in 3Q25 with revenue per hl growth of 4.8% and by 1.8% in 9M25 with revenue per hl growth of 4.5%. Reported revenue increased by 0.6% in 3Q25 to 15 133 million USD and d
Lake.com and Interhome Announce Strategic Partnership to Expand European Lakeside & Waterfront Vacation Rentals30.10.2025 07:00:00 CET | Press release
Lake.com, the vacation-rental marketplace built for life by the water, partnered with Interhome, one of Europe’s most established managers of holiday homes and apartments. The collaboration brings Interhome’s quality-checked villas, chalets, and apartments across 20+ European countries to Lake.com travelers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029035564/en/ Lake.com and Interhome announce partnership with 40,000 new vacation rentals. Today, Interhome’s professionally managed inventory becomes bookable on Lake.com, combining real-time rates and availability with Interhome’s local service offices for key handover, cleaning, and guest support. This marks Lake.com’s European expansion, deepening selection in high-demand lakeside and coastal destinations. Lake.com’s integration with Interhome adds more than 40,000 holiday homes—from Italy’s Lake Garda and Como to Austria’s Salzkammergut, Switzerland’s Lakes Lucerne
Yokogawa to DeliverIntegrated Control Systems for Urban Infrastructure in Green Riyadh Project30.10.2025 02:00:00 CET | Press release
- Contributing to a national urban afforestation initiative that aims to transform the Saudi capital into one of the world's most livable cities - Yokogawa Electric Corporation (TOKYO: 6841) announces that its subsidiary, Yokogawa Saudi Arabia, has been awarded a contract by the Royal Commission for Riyadh City to provide the necessary systems and services for the main command and control center of the Green Riyadh project*. Led by the Government of Saudi Arabia, this national initiative is a key element of Saudi Vision 2030. Its objective is to transform Riyadh into one of the world’s most livable cities through urban greening, enabling residents to lead healthier and more sustainable lives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029727530/en/ Riyadh, Saudi Arabia The project will plant 7.5 million trees across parks, public facilities, healthcare centers, and roads by 2030, increasing green space per capita from
R2 Joins Ant International to Expand Credit Access for SMEs in LATAM30.10.2025 01:04:00 CET | Press release
The investment will enable both companies to integrate their expertise to improve credit access for small and medium-sized enterprises (SMEs) in a region facing a credit gap of over US$1 trillion Ant International, a leading global digital payment, digitisation, and financial technology provider, today announced a strategic investment in R2, the leading embedded lending infrastructure company in Latin America (LATAM), to expand access to credit for SMEs across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029918704/en/ From left to right: Roger Larach, Co-Founder and Chief Executive Officer, R2 | Quan Yu, General Manager of Global Credit Services, Ant International | Roger Teran, Co-Founder and Chief Data Officer, R2 R2 enables digital platforms to offer financing solutions quickly and securely through an API-based, end-to-end white-labeled experience. This allows merchants to easily access capital through th
Axelspace Signs MoUs with Two African Organizations to Address Social Challenges through the Utilization of Satellite Data29.10.2025 21:57:00 CET | Press release
Collaborating with Partners in Ghana and Kenya to Develop and Implement Tailored Solutions Axelspace Corporation (“Axelspace”), which develops and operates microsatellites and conducts business to promote a society where space is accessible to people around the world, is pleased to announce the memorandum of understandings (MoUs) with two governmental organizations of African countries on cooperation for addressing social challenges through the utilization of satellite-based Earth observation (EO) data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029793600/en/ Genevieve Edna Apaloo, Ambassador Extraordinary and Plenipotentiary of the Republic of Ghana to Japan and Yuya Nakamura, President and CEO, Axelspace at the signing ceremony on stage at NIHONBASHI SPACE WEEK 2025 Axelspace signed MoUs individually with the Ghana Space Science and Technology Institute (GSSTI) of the Republic of Ghana, and the Regional Centre for M
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom